摘要
目的利用非线性混合效应模型(NONMEM)法建立伏立康唑的群体药物代谢动力学(Pop PK)模型,探索影响伏立康唑体内处置的生理病理因素,为伏立康唑的临床个体化用药提供依据。方法回顾性地收集2014年5月到2015年4月中南大学湘雅二医院药学部治疗药物监测室监测的患者资料,从中挑选出55名患者,收集86个血药浓度数据点及其生理病理数据(包括人口学数据、实验室数据与合并用药情况),收集的数据使用Phoenix软件构建模型。结果 Pop PK研究最终得到的模型是:CL(m L·min-1)=1.63×[1+(Age-47)×(-0.01)]×[(1+(ALT-42)×0.001]×exp(0.05),V(L)=6.93×exp(1.37×10-7)。结论本研究得到的模型提示老年患者比年轻成年患者有着更低的伏立康唑清除率,丙氨酸转氨酶浓度较高的患者清除率较高,这一结果还需进一步验证。
Objective To estimate the population pharmacokinetics（Pop PK） of voriconazole by nonlinear mixed effect model, identify the factors influencing the pharmacokinetics of voriconazole and provide a basis for voriconazole in the individualized medication. Methods We retrospectively collected the clinical information of 55 patients who were given voriconazole in the Second Xiangya Hospital of Central South University. The following covariates were tested in the patients： demographic factors, laboratory data, and concomitant medications. Our data was used for the model by Phoenix software. Results Our final Pop PK model was established： CL（mL·min^-1） = 1.63×[1 ＋（Age- 47）- 0.01]×[1 ＋（ALT- 42）×0.001]×exp（0.05）, V（L） = 6.93×exp（1.37×10^- 7）. Conclusion Elderly patients have lower voriconazole clearance than young patients; patients with higher alanine aminotransferase also have higher levels of clearance.
出处
《中南药学》
CAS
2015年第11期1174-1177,共4页
Central South Pharmacy
